Cover Image
市場調查報告書

肥大型心肌病治療藥的全球市場:2015∼2023年 - β腎上腺素阻斷劑,鈣離子通道阻斷劑,抗心律不整藥,抗凝血藥的產業分析,開發平台分析,規模,佔有率,成長,趨勢,預測

Hypertrophic Cardiomyopathy Therapeutics Market - Beta Adrenergic Blocking Agents, Calcium Channel Blocker, Antiarrhythmic Agents, and Anticoagulants - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast, 2015 - 2023

出版商 Transparency Market Research 商品編碼 345421
出版日期 內容資訊 英文 78 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
肥大型心肌病治療藥的全球市場:2015∼2023年 - β腎上腺素阻斷劑,鈣離子通道阻斷劑,抗心律不整藥,抗凝血藥的產業分析,開發平台分析,規模,佔有率,成長,趨勢,預測 Hypertrophic Cardiomyopathy Therapeutics Market - Beta Adrenergic Blocking Agents, Calcium Channel Blocker, Antiarrhythmic Agents, and Anticoagulants - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast, 2015 - 2023
出版日期: 2015年11月06日 內容資訊: 英文 78 Pages
簡介

肥大型心肌病是由於心臟肌肉細胞增大而導致心室(通常為左心室)壁加厚而發生肥厚性心肌病。增厚可能會阻止血液流出心室的症狀稱作為閉塞性肥大型心肌病。一般認為現代的醫療基礎設施、年輕人久坐的生活方式增加,肥胖人口的增加等預計推動該市場的擴大。

本報告提供全球肥大型心肌病治療藥市場相關調查、各類藥物趨勢、到2023年的市場成長預測、各地區趨勢,以及打入市場的主要企業簡介彙整。

第1章 序論

第2章 摘要整理

第3章 產業分析

  • 簡介
  • 流行病學與預後:肥大型心肌病
  • 市場趨勢
    • 促進要素
      • 慢性心血管疾病的罹患率上升使有效治療的需求提高
      • 發展中國家對肥大型心肌病的認識提高
    • 阻礙要素
      • 心臟去顫器和心律調節器等設備的技術性升級
    • 機會
      • 標靶治療
  • 市場魅力度分析
  • 競爭環境
  • 市場佔有率:2014年

第4章 各藥物市場

  • 簡介
  • 全球β腎上腺素阻斷劑市場收益
  • 全球鈣離子通道阻斷劑市場收益
  • 全球抗心律不整藥市場收益
  • 全球抗凝血藥市場收益

第5章 開發平台分析

  • 概要
  • 第二期,第一期臨床試驗

第6章 各地區市場

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第7章 建議

  • 搭配診斷提高診斷率擴大最終藥物市場

第8章 企業簡介

  • Astra Zeneca plc
  • Concordia Healthcare Corp.
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd
目錄

This report on the hypertrophic cardiomyopathy therapeutics market studies the current and future prospects of the global market. Hypertrophic cardiomyopathy occurs if heart muscle cells enlarge and cause the walls of the ventricles (usually the left ventricle) to thicken. However, the thickening may block blood flow out of the ventricle and the condition is called obstructive hypertrophic cardiomyopathy. Modern healthcare infrastructure, increasing sedentary lifestyle in young population and rising obese population are expected to propel the global hypertrophic cardiomyopathy therapeutics market.

The hypertrophic cardiomyopathy therapeutics market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments and sub-segments of the market. It also provides information and data analysis of the global hypertrophic cardiomyopathy therapeutics market with respect to the segments based on the type of drug class, and their geographic analysis. A detailed qualitative analysis of driving and restraining factors for the market growth and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global hypertrophic cardiomyopathy therapeutics market.

Based on drug class, the hypertrophic cardiomyopathy therapeutics market has been segmented into four major categories: Beta Adrenergic Blocking Agents, Calcium Channel Blockers, Antiarrhythmic Agents, and Anticoagulants. The market segments have been extensively analyzed based on usefulness, efficacy, revenue, and geographical coverage. The market size and forecast in terms of USD million for each segment has been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2015 to 2023, considering 2014 as the base year.

Geographically, the global hypertrophic cardiomyopathy therapeutics market has been categorized into four major regions and the key countries in the respective region: North America (U.S., Canada), Europe (U.K., Germany, Rest of Europe), Asia Pacific (Japan, India, Rest of Asia Pacific), and Rest of the World (Latin America, Middle East, Africa). The market size and forecast for each of these regions and the mentioned countries has been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. The research study also covers the competitive scenario in these regions.

The report also profiles major players in the global hypertrophic cardiomyopathy therapeutics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include AstraZeneca plc, Concordia Healthcare Corp., Sanofi S.A., Pfizer, Inc., Merck & Co., Inc., Teva Pharmaceuticals Limited, Mylan N.V., Gilead Sciences, Inc., and Novartis AG

The global hypertrophic cardiomyopathy therapeutics market is segmented as follows:

Global Hypertrophic Cardiomyopathy Therapeutics, by Drug Class

  • Beta Adrenergic Blocking Agents
  • Calcium Channel Blockers
  • Antiarrhythmic Agents
  • Anticoagulants

Global Hypertrophic Cardiomyopathy Therapeutics, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • India
    • Japan
    • Rest of Asia Pacific
  • Rest of the World
    • Latin America
    • Middle East
    • Africa

Table of Contents

1. Preface

  • 1.1. Report Description
  • 1.2. Market Segmentation
  • 1.3. Research Methodology

2. Executive Summary

  • 2.1. Hypertrophic Cardiomyopathy Therapeutics: Market Snapshot
  • 2.2. Global Hypertrophic Cardiomyopathy Therapeutics Market Share, by Geography, 2014 & 2023 (Value %)
  • 2.3. Global Hypertrophic Cardiomyopathy Therapeutics Market, by Drug Class, 2014 (US$ Mn)

3. Hypertrophic Cardiomyopathy Therapeutics Market - Industry Analysis

  • 3.1. Introduction
  • 3.2. Epidemiology and Prognosis: Hypertrophic Cardiomyopathy
  • 3.3. Market Dynamics
    • 3.3.1. Drivers
      • 3.3.1.1. Driver 1: Increasing prevalence of chronic cardiovascular diseases to increase demand for effective treatments
      • 3.3.1.2. Driver 2: High awareness associated with HCM in developed countries
    • 3.3.2. Restraints
      • 3.3.2.1. Restraint 1: Rising technological upgradation in devices such as defibrillators and pacemakers
    • 3.3.3. Opportunities
      • 3.3.3.1. Opportunity 1: Targeted therapy for hypertrophic cardiomyopathy
  • 3.4. Market Attractiveness Analysis - Hypertrophic Cardiomyopathy Therapeutics Market, by Geography, 2014
  • 3.5. Competitive Landscape
  • 3.6. Global Hypertrophic Cardiomyopathy Therapeutics Market Share, by Key Players, 2014 (%)

4. Market Segmentation - By Drug

  • 4.1. Introduction
    • 4.1.1. Global Hypertrophic Cardiomyopathy Therapeutics Market Revenue, by Drug Class, 2013-2023 (US$ Mn)
  • 4.2. Global Beta Adrenergic Blocking Agents Market Revenue, 2013-2023 (US$ Mn) and Analysis
  • 4.3. Global Calcium Channel Blockers Market Revenue, 2013-2023 (US$ Mn) and Analysis
  • 4.4. Global Antiarrhythmic Agents Market Revenue, 2013-2023 (US$ Mn) and Analysis
  • 4.5. Global Anticoagulants Market Revenue, 2013-2023 (US$ Mn) and Analysis

5. Pipeline Analysis

  • 5.1. Overview
  • 5.2. Phase II and Phase I Clinical Trials

6. Market Segmentation - By Geography

  • 6.1. Introduction
    • 6.1.1. Global Hypertrophic Cardiomyopathy Therapeutics Market Revenue, by Region, 2013-2023 (US$ Mn)
  • 6.2. North America Hypertrophic Cardiomyopathy Therapeutics Market Revenue, by Country, 2013-2023 (US$ Mn)
    • 6.2.1. U.S. Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013-2023, (US$ Mn)
    • 6.2.2. Canada Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013-2023, (US$ Mn)
  • 6.3. Europe Hypertrophic Cardiomyopathy Therapeutics Market - Revenue, by Country, 2013-2023 (US$ Mn)
    • 6.3.1. U.K. Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013-2023, (US$ Mn)
    • 6.3.2. Germany Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013-2023, (US$ Mn)
    • 6.3.3. Rest of Europe Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013-2023, (US$ Mn)
  • 6.4. Asia Pacific Hypertrophic Cardiomyopathy Therapeutics Market Revenue, by Country, 2013-2023 (US$ Mn)
    • 6.4.1. India Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013-2023, (US$ Mn)
    • 6.4.2. Japan Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013-2023, (US$ Mn)
    • 6.4.3. Rest of APAC Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013-2023, (US$ Mn)
  • 6.5. Rest of the World Hypertrophic Cardiomyopathy Therapeutics Market Revenue, by Country, 2013-2023 (US$ Mn)
    • 6.5.1. Latin America Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013-2023, (US$ Mn)
    • 6.5.2. Middle East Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013-2023, (US$ Mn)
    • 6.5.3. Africa Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013-2023, (US$ Mn)

7. Recommendations

  • 7.1. Recommendation 1: Companion diagnostics would help to increase the diagnostic rate and ultimately the drugs market

8. Company Profiles

  • 8.1. Astra Zeneca plc
  • 8.2. Concordia Healthcare Corp.
  • 8.3. Gilead Sciences, Inc.
  • 8.4. Merck & Co., Inc.
  • 8.5. Mylan N.V.
  • 8.6. Novartis AG
  • 8.7. Pfizer, Inc.
  • 8.8. Sanofi S.A.
  • 8.9. Teva Pharmaceutical Industries Ltd
Back to Top